



18 April 2024

National Stock Exchange
1 Bligh Street
Sydney NSW 2000

Attn: Kristina Gjeleska, Admissions Manager

By email: Kristina.Gjeleska@nsx.com.au

Dear Kristina Gjeleska,

Re: GO-Dx Corporation (Aust) Ltd – NSX Appendix 1 Admission Letter

We refer to previous communications between GO-Dx Corporation (Aust) Ltd (ACN 673 839 613) (**Company**) and the National Stock Exchange of Australia (**NSX**).

The Company now wishes to provide a formal letter of application to the official list of the NSX, as required by, and in the form prescribed by, Appendix 1 of the NSX Listing Rules.

Please find enclosed the Company's Prospectus (**Prospectus**), which has been prepared in compliance with NSX Listing Rule 4.4 and Appendix 1 of the NSX Listing Rules. The Prospectus is incorporated by reference into this application letter.

1. General

(a) The name of the applicant and the date and place of incorporation.

The applicant is GO-Dx Corporation (Aust) Ltd ACN 673 839 613 a company incorporated on 22 December 2023 in Victoria, Australia.

(b) If not incorporated in Australia, the date on which the applicant became registered under the Corporations Act.

Not applicable.

(c) The address of the principal registered office and the address of each office at which a share register is kept.

The address of the Company's principal registered office is Level 6, 505 Little Collins Street, Melbourne VIC 3000.

The Company's share register is kept by the Company's share registry, Automic Group, whose offices are located at Level 5, 126 Phillip Street, Sydney NSW 2000.

(d) Formal request for the listing of the securities in respect of which the application is made, specifying the nature of the securities and the amount, class, the voting rights attached and whether they are to be fully paid.

The Company now makes a formal request for the listing of up to 21,052,632 fully paid ordinary shares in the capital of the Company (**Shares**) in respect of which the application is made. Each shareholder is entitled to one vote on a show of hands/one vote for each Share.

- (e) **The proposed method by which the securities are to be brought to listing and details of any proposed distribution of the securities.**

This application is brought by the Company in compliance with Listing Rule 4.4 for the listing of equity securities as a new applicant as part of an Initial Public Offering (IPO).

- (f) **The estimated market capitalisation of the securities for which a listing is sought.**

The estimated market capitalisation of the Company's securities following listing will be \$69,427,000 based on there being 21,052,632 Shares on issue at listing with a price per share of \$0.38.

- (g) **An estimate of the net proceeds of any proposed issue and the intended use of the proceeds.**

The Company is seeking to raise between \$5,000,000 to \$8,000,000 to be used towards achieving its business objectives in furthering the development of its medical diagnostic technologies and other health and wellbeing products. The Company is in the biotech and medical industry, pioneering development with regard to personalised Ribonucleic acid (RNA) maps to support precision wellness and precision medicine, in particular immunity, anti-ageing, neural health and specific cancers.

- (h) **The name of any other stock exchange on which any securities of the issuer are already listed and/or traded.**

Not applicable.

2. Share capital and ownership

- (a) **A list in tabular form of:**

- (i) **the designation or title of each class of share;**

The Company has ordinary fully paid shares only.

- (ii) **the number of shares issued;**

As at the date of this application, the Company has 161,650,000 fully paid ordinary shares on issue. Subject to the Company obtaining NSX approval under this application, completion of its seed capital raisings and shares issued to Distributors, Partners and Advisors, the Company will have 182,702,632 fully paid ordinary shares on issue.

- (iii) **the voting rights attached to each share;**

Please refer to Section 3.11 of the Prospectus for a summary of the voting rights attached to Shares.

- (iv) **The amount of fully paid up shares;**

All Shares on issue in the Company are fully paid up.

- (v) **The shareholdings of the directors and officers of the issuer;**

The shareholdings of the directors and officers of the Company at the date of this application and as anticipated at completion of the Offer, are set out in Section 5.3.1 of the Prospectus.

- (vi) **so far as is known, or can be ascertained after reasonable enquiry, the names of all shareholders of the issuer who own five percent (5%) or more of the shares of the issuer and their respective shareholdings.**

The names of all shareholders of the Company who own 5% or more of the Shares and their respective shareholdings are set out at Section 5.6 of the Prospectus.

- (b) A list in tabular form of the names of all shareholders of the issuer including the dates that the shares were allotted to them, the consideration that they provided and the number of shares that are held.**

Please refer to the security holder register of the Company enclosed with this application.

3. Securities

An outline of the principal terms of the securities the applicant wishes to list.

Please refer to Section 3.11 of the Prospectus for a summary of the key rights and liabilities attaching to the Shares that the Company wishes to list.

4. History and Nature of Business

- (a) A short introductory paragraph describing the general nature of the business and products of the applicant.**

The Company is in the biotech and medical industry pioneering development and innovation with regard to personalised RNA maps to support precision wellness and precision medicine, in particular, immunity, anti-ageing, neural health and specific cancers. Specifically, the Company:

- is developing and commercialising its own RNA Mapping Platform, RNA Analytical Platform as well as microRNA (**miRNA**) technology;
- has developed its own mobile application known as the Wellness 365 App, which provides a marketplace for health and diagnostic products;
- is developing scientific methods using miRNA-based diagnostics for cancers.

In addition, the Company has various artificial intelligence (**AI**) collaborations in the diagnostic space to develop an AI-enabled Platform to augment the RNA Mining/Mapping Platform and RNA Analytical Platform.

Please refer to Section 2 of the Prospectus for further information on the business operations of the Company.

- (b) A brief history of the issuer for the last five (5) years or, if later, from inception to the date of the application.**

Although the Company was incorporated in 2023, it operates its business via GO-Dx Corporation Singapore, its wholly-owned subsidiary incorporated in Singapore.

GO-Dx Corporation Singapore was incorporated on 3 August 2019 with a primary focus on research and experimental development in medical science. The Company has since been pioneering biomedical technology in rapid diagnostics, leveraging artificial intelligence and data analytics to empower individuals with personalised and effective healthcare products and solutions.

Since incorporation, the Company offers products and has the rights to distribute products in various Asian territories including:

- “G’Nest Deluxe” and “G’Nest Premium” products manufactured and supplied by FEGO Biotech Pte Ltd and
- “C’Neuros” product manufactured and supplied by NGF Bioenterprise Pte Ltd

(Products Range)

The Company also offers diagnostic testing and analysis services including:

- RNA Mining/Mapping & Analytics Platform;
- AI-Enabled Platform;
- Cancer Screening and Diagnostics;
- Neurological and Immunological Precision Medicine via Proprietary Genetic and Epigenetic Screening and Diagnostic Platforms;
- Chronic/Infectious Disease Prediction via Proprietary DNA Profiling and Fluorescence In Situ Hybridisation (**FISH**) Platforms;
- Liquid Biopsy Based Diagnostics for cancers using Next-Generation Sequencing (**NGS**) technology

(Services Range).

For more information on the Products Range and Services Range, please refer to Section 2.3 of the Prospectus.

- (c) A description of the business now conducted by the issuer and its child entities, including principal products manufactured, services performed or investments held, principal markets for products and raw materials, method of marketing, annual turnover for the preceding three financial years and for the current financial year to the latest date available.**

Refer to Section 2 of the Prospectus for information on the business now conducted by the Company.

5. Summary of Earnings

A summary of earnings, on a consolidated basis if the applicant has subsidiaries, for the last three (3) financial years, showing sales, earnings before charges for depreciation, interest and tax (if any), the amount of each of those charges, net income before extraordinary items, extraordinary items, net income and earnings per share.

Please refer to Section 7.6.1 of the Prospectus.

6. Tabulation of Balance Sheet

A tabulation of its balance sheet for each of the last three (3) financial years (on a consolidated basis if the issuer has subsidiaries) or from the date of incorporation, if shorter. The tabulation should include a calculation of the net asset value per security for each of the three (3) financial years.

Please refer to Section 7.6.3 of the Prospectus.

7. Employees

A statement as to the total number of persons regularly employed and, if subject to seasonal fluctuations, the maximum and minimum numbers employed during the preceding twelve (12) months.

The Company has 18 employees.

8. Child Entities

A tabular list of all child entities showing in respect of each such corporation:

(a) the name of the corporation;

The Company has "child entities" pursuant to the definition of that term contained in the NSX Listing Rules, being:

- a) its wholly-owned subsidiary GO-Dx Corporation Singapore, registered in Singapore as GO-Dx Corporation Ltd (UEN 201925421H);
- b) 99.99% of GO-Dx Philippines Inc., a subsidiary registered in the Philippines;
- c) 99.99% of PT GODx Corp Indonesia, a subsidiary registered in Indonesia.

(b) A brief statement of the nature of its business and its relationship to the operations of the entire enterprise; and

As articulated above in response to question 4(b) above, the Company operates its business through GO-Dx Corporation Singapore.

GO-Dx Philippines Inc and PT GODx Corp Indonesia were incorporated with the purpose to facilitate product registration and to obtain import licences in the Philippines and Indonesia respectively, with no current business activities as yet.

(c) share capital by classes, showing the amount issued and the amount owned by the holding entity.

The Company owns 100% of the ordinary shares in GO-Dx Corporation Singapore.

9. Dividend Record

State the number of consecutive years in which dividends have been paid. State the amount of dividend (per share and in the aggregate) paid by the applicant (and its child entities) for each of the three (3) preceding years. Indicate whether dividends have been paid on a quarterly, semi-annual or annual basis. State the record date, payment date and the date of declaration with respect to each dividend paid during the past two (2) years.

To date, no dividends have been paid by the Company since incorporation.

10. Properties

Describe briefly the general character of the properties of the applicant and its child entities, including:

(a) location;

The Company does not occupy any real property whether owned or leased in Australia. The Company's registered office is Level 6, 505 Little Collins Street, Melbourne Victoria 3000 which is the office of its legal advisor, Moray & Agnew

Lawyers, and such address is used by the Company as its registered office on an on-going basis with permission.

The child entity, GO-Dx Corporation Singapore, is located at 3 Little Road #07-02 CRF Building, Singapore 536982 (**Office**). This location is not owned by GO-Dx Corporation Singapore (it is a sub-lessee).

GO-Dx Corporation Singapore has a laboratory located at 81 UB One Building, UB Avenue 4, Singapore 408830 (**Laboratory**). This location is not owned by GO-Dx Corporation Singapore (it is a lessee).

GO-Dx Philippines Inc and PT GODx Corp Indonesia were incorporated with the purpose to facilitate product registration and to obtain import licences in the Philippines and Indonesia respectively, with no physical office or laboratory as yet.

(b) land area;

Not applicable for the Company.

The child entity, GO-Dx Corporation Singapore occupies a land area of:

- 1200sft for the Office; and
- 1100sft for the Laboratory.

(c) number of buildings;

Not applicable for the Company.

The child entity, GO-Dx Corporation Singapore is located in two (2) separate buildings – one for the Office and one for the Laboratory, but does not occupy all the floors in each of the building.

(d) aggregate floor area of buildings; and

Not applicable for the Company.

The child entity, GO-Dx Corporation Singapore has a total floor area of as described above in response to question 10(b) above.

(e) whether properties are owned or leased, and if leased, state total rental paid for each of the three (3) preceding financial years and average term of years.

Not applicable for the Company.

The child entity, GO-Dx Corporation Singapore leases the Office and Laboratory and has paid \$9,349 in rent for the past preceding financial years. The Office and Laboratory are leased on a yearly renewal basis.

11. Litigation

Particulars of any litigation or claims of material importance made against any member of the group in the last five (5) years or which is pending or threatened against any member of the group, or an appropriate negative statement.

Neither the Company nor GO-Dx Corporation Singapore have any pending or threatened litigation proceedings or claims of material importance.

12. Management:

- (a) **the full name, residential address and description (being his or her qualifications or area of expertise or responsibility) of every director or proposed director and any person who performs an important administrative, management or supervisory function and particulars of the principal functions performed by each of them within the group if significant to the group;**

The directors of the Company are:

- (i) Mr Sah Soon LIM (Executive Director), resident at 22 Pheng Geck Avenue, Sennett Estate, Singapore 348217, is appointed as a Executive Director and will be based in Singapore.
- (ii) Mr Matthew LEONARD (Non-Executive Director), resident at 14 Beacon Point Road, Clifton Springs VIC 3222, is appointed as a Non-Executive Director and will be based in Australia.
- (iii) Mr Justyn STEDWELL (Non-Executive Director), resident at 29 Freeman Street, Yarraville VIC 3013, is appointed as a Non-Executive Director and will be based in Australia.
- (iv) Dr Kah Meng LIM (Group Managing Director, Chief Technical Officer and Chief Executive Officer), resident at 13 Fowlie Road, Singapore 428503. Dr Lim is responsible for overseeing the day-to-day operations of the Company's business.

The persons who perform an important administrative, management or supervisory function are:

- (i) Dr Kah Meng LIM (Group Managing Director, Chief Technical Officer and Chief Executive Officer), resident at 13 Fowlie Road, Singapore 428503. Dr Lim is responsible for overseeing the day-to-day operations of the Company's business.
- (ii) Mr Danny HENG (Chief Financial Officer) of 132A Hillview Avenue, Montrose Condominium, Singapore 669604. Mr Heng is responsible for managing the financial operations of the Company's business.
- (iii) Dr Ron TAN (Chief Scientific Officer) of Blk 31, Bishan Street 11, #08-06, Singapore 579819. Dr Tan is responsible for managing the science and research operations of the Company's business.
- (iv) Mr Bill PAVLOVSKI (Company Secretary) of 1/5 Oslo Way, Keilor Downs, VIC 3038. Mr Pavlovski is responsible for the company secretarial functions of the Company and for liaising with the NSX.

Please refer to section 5 of the Prospectus for further detail on the above persons.

- (b) **the nature of any family relationship between the persons mentioned in (a);**

Not applicable.

- (c) **a brief account of the business experience of each of these persons during the last five (5) years;**

Please refer to Section 5.1 of the Prospectus for the directors' profiles, and Section 5.2 of the Prospectus for the key management personnels' profile. These profiles include details of the experience of each of these persons during the last 5 years.

(d) indicate any other directorships held by each director or proposed director in any publicly listed or traded companies; and

- (i) Mr Justyn STEDWELL is currently a company secretary of Lightning Minerals Limited (ASX:L1M), an Australian public company listed on the ASX. He is also a company secretary of Spenda Limited (ASX:SPX).
- (ii) Mr Matthew LEONARD is currently an executive director of BPH Global Limited (ASX:BP8) (formerly Stemcell United Limited (ASX:SCU)), an Australian public company listed on the ASX. He is also a Non-Executive Director of Agri Skylight Limited (NSX:AGS).
- (iii) Lim Kah Meng is currently an Independent Director for Singapore Paincare Holdings Limited, a company listed on SGX Catalyst.

(e) state if any director or proposed director has, in any jurisdiction, been convicted in any criminal proceeding or has had a bankruptcy petition filed against him or her or any partnership in which he was a partner or any body corporate of which he was a director or has been sanctioned or otherwise disciplined by any self regulatory securities association of which he or she is or has been a member or any securities supervisory or regulatory body or any such event is pending.

Not applicable.

13. Sponsors, bankers, etc:

(a) the names and addresses of the issuer's sponsor, financial advisers, principal bankers, nominated adviser, share registrar/transfer agent and solicitors; and

(i) Sponsor

Not applicable.

(ii) Accounting / Taxation Advisors:

The Company has engaged Mr Danny HENG as Chief Financial Officer to oversee the accounting function.

(iii) Principal Bankers

The Company has appointed Westpac Banking Corporation.

(iv) Nominated Advisor

The Company has appointed Moray & Agnew Lawyers as its Nominated Advisor.

(v) Share Registry

The Company has appointed Automic Group of Level 5, 126 Phillip Street, Sydney NSW 2000 as its Share Registry.

(vi) Solicitors

Moray & Agnew Lawyers of Level 6, 505 Collins Street, Melbourne VIC 3000 act as the Company's Australian solicitors.

Amica Law LLC of 77, #22-01 Robinson Rd, Robinson 77, Singapore 068896 was engaged by the Company to act as the Company's Singaporean IP solicitors.

- (b) the name, address and professional qualifications of the issuer's auditors.**

HLB Mann Judd (Vic) Partnership ABN 20 696 861 713 of Level 9, 575 Bourke Street Melbourne VIC 3000.

- 14. A statement of any requirements of the Listing Rules which cannot be met by the applicant and detailed arguments to support any request for a waiver or modification of the normal requirements.**

Listing Rule 2.2 requires that a new applicant for listing must be sponsored by a participant of the Exchange. The Company has submitted a waiver from this requirement to appoint a sponsor.

The Company will apply for a waiver of NSX Listing Rule 2.2, so that the Company does not have to appoint a sponsoring broker for the purposes of the IPO and Listing.

- 15. A declaration, stated to be to the best of the issuer's knowledge, information and belief that:**

- (a) save as specified in the application letter, all the qualifications for listing set out in Chapter 3 of Section IIA of the Listing Rules have, in so far as applicable and required to be met and fulfilled prior to application, been met or fulfilled in relation to the issuer and the securities of the issuer the subject of the application;**
- (b) all information required to be included in the disclosure document pursuant to Rule 4.8 and the Corporations Act will be included; and**
- (c) there are no other facts bearing on the issuer's application for listing, which, in the issuer's opinion, should be disclosed to the Exchange.**

The Company declares that, to the best of its knowledge, information and belief:

- (i) save as specified in the Company's application letter, all the qualifications for listing set out in Chapter 3 of Section IIA of the Listing Rules have, in so far as applicable and required to be met and fulfilled prior to application, been met or fulfilled in relation to the Company and the securities of the Company the subject of the application;
- (ii) all information required to be included in the Company's disclosure document pursuant to Rule 4.8 and the Corporations Act will be included; and
- (iii) there are no other facts bearing on the Company's application for listing, which, in the issuer's opinion, should be disclosed to the NSX.

If you would like to discuss this matter, or require any further information, then please do not hesitate to contact the Company.

Yours faithfully,



Dr Kah Meng LIM
Executive Chairman

